Information Provided By:
Fly News Breaks for December 19, 2019
DGX
Dec 19, 2019 | 06:51 EDT
BofA/Merrill analyst Derik de Bruin upgraded Quest Diagnostics to Neutral from Underperform with a price target of $110, up from $94. The analyst notes that investor sentiment on medical laboratories may be stabilizing given the sector's lower macro economic exposure and "not challenging" valuations. de Bruin adds that Quest Diagnostics navigated industry headwinds "better than expected".
News For DGX From the Last 2 Days
There are no results for your query DGX